Scott Rocklage, a doctor, and a Venture Partner of 5AM Ventures went to California University, Berkely and graduated with a B.Sc in Chemistry. Dr. Rocklage later advanced his studies at MIT(Massachusetts Institute of Technology) where he obtained a Doctor of Philosophy in Chemistry. In the year 2003, Dr. Scott made his move and joined the 5AM Ventures. After one year Scott Rocklage proceeded to be the 5AM’s Managing Partner. Scott has over thirty years of experience with vital leadership duties and healthcare management. Dr. Rocklage has worked as the Chairperson and Chief Executive Officer of Cubist Pharmaceuticals, Chairperson, and CEO of Nycomed Interventional and held another R&D post at Catalytica and Salutar. These duties imposed on Scott led to the FDA acceptance of three United States New Drug Applications(Teslascan, Cubicin, and Omniscan).


Expansion Therapeutics has been trying to get funds to fight genetic disorders that have been known of leading muscular dystrophy in grown-ups. Sign and symptoms begin to show when RNA gets to toxic levels.DM1 (Myotonic dystrophy type I condition) occurs when some of the RNA being produced inside the cells reach dangerous levels causing some parts of the heart, hormonal system, respiratory system and the central nervous system not to be functional. Expansion Therapeutics makes drugs that fight the RNA in illnesses that are as a result of RNA, the research being headed by Dr. Disney and Dr. Scott Rocklage being a part of the team. 5AM Ventures, Sanofi Ventures, and Novartis Ventures were also involved in financing in the cause for fighting this disorders.


Dr. Scott Rocklage is presently the Board Chairperson for Cidara, Rennovia, and Kinestral. He has also been on various boards such as Variation Biotechnologies, WaveRX, Epirus Biopharmaceuticals, and Pulmatrix. Scott Rocklage also held the position of Executive chairperson of Semprus, Miikana, and Ilypsa. He additionally filled in as the Independent Director of Zalicus. Currently, Scott works in MA office located in Boston. Learn more:

May 17, 2018

Leave a Reply

Your email address will not be published. Required fields are marked *